Atypical antipsychotics: Difference between revisions
From Proteopedia
Jump to navigationJump to search
New page: ==Your Heading Here (maybe something like 'Structure')== <StructureSection load='1stp' size='340' side='right' caption='Caption for this structure' scene=''> The atypical antipsychotics (A... |
No edit summary |
||
| (3 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
<StructureSection load='' size='340' side='right' caption='Aripiprazole' scene='95/958562/Cv/1'> | |||
<StructureSection load=' | The atypical antipsychotics (AAP), also known as second generation antipsychotics (SGAs) and serotonin–dopamine antagonists (SDAs),<ref name='a1'>PMID: 23006237</ref><ref name='a2'>Sadock BJ, Sadock, Virginia A., Ruiz, Pedro (2014). Kaplan & Sadock's Synopsis of Psychiatry: Behavioral Sciences/Clinical Psychiatry (11th ed.). Philadelphia: Wolters Kluwer. p. 318. ISBN 978-1-60913-971-1. OCLC 881019573</ref> are a group of antipsychotic drugs (antipsychotic drugs in general are also known as tranquilizers and neuroleptics, although the latter is usually reserved for the typical antipsychotics) largely introduced after the 1970s and used to treat psychiatric conditions. Some atypical antipsychotics have received regulatory approval (e.g. by the FDA of the US, the TGA of Australia, the MHRA of the UK) for schizophrenia, bipolar disorder, irritability in autism, and as an adjunct in major depressive disorder. See also [https://en.wikipedia.org/wiki/Atypical_antipsychotic Atypical antipsychotic]. | ||
The atypical antipsychotics (AAP), also known as second generation antipsychotics (SGAs) and serotonin–dopamine antagonists (SDAs), | |||
*[[Aripiprazole]] | |||
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> | ||
Latest revision as of 15:37, 22 February 2024
| ||||||||||||
